Your browser doesn't support javascript.
loading
PYY, a Therapeutic Option for Type 2 Diabetes?
Guida, Claudia; Ramracheya, Reshma.
Afiliação
  • Guida C; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Ramracheya R; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Clin Med Insights Endocrinol Diabetes ; 13: 1179551419892985, 2020.
Article em En | MEDLINE | ID: mdl-32030069
ABSTRACT
Metabolic surgery leads to rapid and effective diabetes reversal in humans, by weight-independent mechanisms. The crucial improvement in pancreatic islet function observed after surgery is induced by alteration in several factors, including gut hormones. In addition to glucagon-like peptide 1 (GLP-1), increasing lines of evidence show that peptide tyrosine tyrosine (PYY) plays a key role in the metabolic benefits associated with the surgery, ranging from appetite regulation to amelioration of islet secretory properties and survival. Here, we summarize the current knowledge and the latest advancements in the field, which pitch a strong case for the development of novel PYY-based therapy for the treatment of diabetes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article